Skip to Main Content

Paper Details

Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
Mult Scler Relat Disord
7
2022
Author NameAffiliation
Yuko ShimizuTokyo Women's Medical University School of Medicine
Atsushi UmemuraClinical Research Center and Department of Neurology, National Hospital Organization Utano National Hospital
  • 1 - 2

Datasets

Release 1.2